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Background: This study sought to establish the long-term effects of Covid-19 following hospitalisation.
Methods: 327 hospitalised participants, with SARS-CoV-2 infection were recruited into a prospective multi-
centre cohort study at least 3 months post-discharge. The primary outcome was self-reported recovery at
least ninety days after initial Covid-19 symptom onset. Secondary outcomes included new symptoms, dis-
ability (Washington group short scale), breathlessness (MRC Dyspnoea scale) and quality of life (EQ5D-5L).
Findings: 55% of participants reported not feeling fully recovered. 93% reported persistent symptoms, with
fatigue the most common (83%), followed by breathlessness (54%). 47% reported an increase in MRC dys-
pnoea scale of at least one grade. New or worse disability was reported by 24% of participants. The EQ5D-5L
summary index was significantly worse following acute illness (median difference 0.1 points on a scale of 0
to 1, IQR: -0.2 to 0.0). Females under the age of 50 years were five times less likely to report feeling recovered
(adjusted OR 5.09, 95% CI 1.64 to 15.74), were more likely to have greater disability (adjusted OR 4.22, 95% CI
1.12 to 15.94), twice as likely to report worse fatigue (adjusted OR 2.06, 95% CI 0.81 to 3.31) and seven times
more likely to become more breathless (adjusted OR 7.15, 95% CI 2.24 to 22.83) than men of the same age.
Interpretation: Survivors of Covid-19 experienced long-term symptoms, new disability, increased breathless-
ness, and reduced quality of life. These findings were present in young, previously healthy working age
adults, and were most common in younger females.
Funding: National Institute for Health Research, UK Medical Research Council, Wellcome Trust, Department
for International Development and the Bill and Melinda Gates Foundation.
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Evidence before this study
 Long-term symptoms after hospitalisation for Covid-19
have been reported, but it is not clear what impact this has
on quality of life.
 It is not known which patient groups are most likely to
have long-term persistent symptoms following hospitalisa-
tion for Covid-19, or if this differs by disease severity.
Added value of this study
 More than half of patients reported not being fully recov-
ered several months after onset of Covid-19 symptoms.
 New or worse disability was reported in a quarter of partic-
ipants.
 EQ5D-5L summary index suggests that quality of life was
significantly reduced by about 10%.
 Females under 50 and those with more severe acute dis-
ease in-hospital had the worst long-term outcomes.
Implications of all available evidence
 Policy makers need to ensure there is long-term support
for people experiencing long-Covid and should plan for
lasting long-term population morbidity. Funding for
research to understand mechanisms underlying long-
Covid and identify potential interventions for testing in
randomised trials is urgently required.1. Introduction
Our understanding of long-term outcomes after acute Covid-19
remains limited. It is becoming increasingly evident that some patients
who have had acute Covid-19 go on to experience persistent symp-
toms, known as long-Covid or post-Covid syndrome [1]. Several stud-
ies in hospitalised and community settings have identified that those
with Covid-19 frequently develop long-term symptoms and a range of
sequelae affecting the kidneys, lungs and heart [15]. These symptoms
appear to overlap with other post-viral syndromes and with the chal-
lenges faced by patients recovering from other critical illness with
post-intensive care syndrome (PICS), such as muscle weakness, fatigue,
and sleep disturbance [610]. Yet, understanding the impact Covid-19
has on patient reported outcome measures, including quality of life,
has not yet been fully characterised [11].
Many clinical trials or studies that aim to characterise the immedi-
ate course of Covid-19 have used mortality as a primary outcome
[12,13]. This has demonstrated that patients in older age groups and
those who have pre-existing comorbidities are at higher risk of dying
from the disease [1417]. Nonetheless, most people with Covid-19 will
survive the initial acute infection and data on what happens to these
individuals in the long-term are lacking. The large number of people
affected by Covid-19 and the growing evidence of long-term sequelae
highlights the importance for policy makers, society and healthcare
systems to understand the difficulties faced by those suffering from
long-Covid [4,18,19]. Understanding the burden of disease, and who is
at greatest risk of developing long-term complications, may help to tar-
get preventative strategies and provide effective support for affected
individuals to improve Covid-19 outcomes and reduce risk of widening
health inequalities by inadequate rehabilitation and recovery support.
Identifying which patient groups are most likely to be affected could
provide data to guide policy and aid future research to identify disease
mechanisms, and to formulate and test new interventions.
The objective of this study was to characterise long-term patient
reported outcomes in individuals who survived hospitalisation for
Covid-19, in those who engaged with post hospital follow-up, using
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Consortium (ISARIC) WHO Clinical Characterisation Protocol (CCP-
UK) and follow-up protocol [20].
2. Methods
2.1. Study design and setting
The ISARIC WHO Clinical Characterisation Protocol (CCP) was first
developed by international consensus in 2012 to respond to any
emerging or re-emerging pathogen of public health interest [21]. It
was activated in the UK in response to the SARS-CoV-2 pandemic on
17th January 2020. Study information including the CCP-UK and post
hospital follow-up protocol, standardised case report forms, study
information and consent forms, are available on the ISARIC4C.net
website. Hospitals providing acute care throughout the United King-
dom were eligible to enrol participants into the study. This analysis is
reported in line with the Strengthening the Reporting of Observa-
tional Studies in Epidemiology (STROBE) guidelines [22].
2.2. Participants
Patients aged 18 years and over, admitted to hospital between
17th January to 5th October 2020 with confirmed or highly suspected
SARS-CoV-2 infection at 31 centres, who consented to be contacted
for post hospital follow-up and were discharged at least 90 days ago
were eligible for inclusion. Participants experienced post-Covid
sequelae without formal treatment as management pathways for
long Covid were not available at this time. Confirmation of SARS-
CoV-2 was by reverse-transcriptase polymerase chain reaction (RT-
PCR). Individuals with clinically diagnosed highly suspected, Covid-
19 were also eligible for inclusion, given that SARS-CoV-2 was an
emergent pathogen in the earlier stages of the pandemic and labora-
tory confirmation was dependent on local availability of PCR testing.
2.3. Variables
Patient questionnaires for adults were developed by a multidisci-
plinary team of researchers, clinicians and psychologists through a
series of meetings and e-mail iterations [21]. These were piloted in
three countries before being finalised. The UK version was piloted
with patients at sites in Liverpool and Glasgow. Patient question-
naires were designed to allow self-assessment via post, or clinician-
led follow up via telephone, or in outpatient clinic, to support wide
dissemination. All surviving patients who consented to be contacted
following discharge, and for whom a valid address or phone number
were provided, were contacted. Questionnaires were posted from the
Outbreak Laboratory coordinating centre at the University of Liver-
pool, UK, with a prepaid, self-addressed envelope for returning the
questionnaire. A combination of postal and telephone follow-up was
used to improve response rates. Those who did not respond by post
and who had a valid phone number were followed up by telephone
or in outpatient clinic by local study investigators. Participants com-
pleted one questionnaire as part of this study, so there were no
repeat measures. Data from responses were entered onto a Research
Electronic Capture (REDCap) Database system hosted at the Univer-
sity of Oxford and linked with data documented during the admission
with acute Covid-19 for the analysis.
Explanatory variables at the time of hospital admission, including
age, sex, pre-existing comorbidities, and treatment received during
the hospital admission were recorded. Maximum severity of Covid-
19 during the acute hospital admission with Covid-19 was classified
using the WHO COVID-19 ordinal severity scale [23]. This scale com-
prised of 4 levels of severity which were relevant to our in-hospital
cohort; level 3 - did not receive supplemental oxygen, level 4 -
received supplemental oxygen, level 5 - received high flow oxygen orPlease cite this article as: L. Sigfrid et al., Long Covid in adults discharged
study using the ISARIC WHO Clinical Characterisation Protocol, The
lanepe.2021.100186NIV non-invasive ventilation (HFNC, NIV), and levels 6 and 7 -
received invasive mechanical ventilation or admission to critical care
[23]. We also used the WHO severity scale to account for in-hospital
severity in our modelling approach [23,24].
2.4. Outcomes
The primary outcome was self-reported recovery at 3 to 12
months following initial Covid-19 symptoms. Secondary outcomes
included persistent or new symptoms, new or worsened disability
assessed using the Washington Disability Group (WG) Short Form
[25], breathlessness measured using the Medical Research Council
(MRC) dyspnoea scale [26], fatigue measured on a 1 to 10 visual ana-
logue scale (VAS) where zero is no fatigue and ten is worst possible
fatigue, and quality of life using the EuroQol EQ5D-5L instrument
(Supplementary Appendix 2) [27]. The MRC dyspnoea scale was
developed to grade the effect of breathlessness on daily activities
[26]. This 5-point scale measures perceived respiratory disability,
with 1 being no breathlessness and 5 being unable to undertake
activities of daily living due to breathlessness [26]. The WG Short Set
tool includes six questions on functioning (vision, hearing, mobility,
cognition, self-care, communication) [25]. These questions reflect a
bio-psychosocial model of disability by describing level of disability
and probe aspects of disability which may limit an individual’s partic-
ipation in society. This tool has been shown to detect the majority of
disabilities and is standardised for use globally [25]. The Euro-
QolEQ5D-5L tool was used to measure psychosocial health and
quality of life [27]. The tool covers five dimensions: mobility, self-
care, usual activities, pain/discomfort and anxiety/depression. The
person indicates his/her health state for each of the five dimensions.
To compare the change in EQ5D-5L at the time of post-hospital fol-
low-up to before Covid-19 onset, we asked patients the same ques-
tions contained in the EQ5D-5L with the tense altered to ask
specifically about pre-Covid-19 state.
2.5. Statistical methods
Categorical data were summarised as frequencies and percen-
tages, and continuous data as median, alongside the corresponding
interquartile range (IQR) presented as the 25th and 75th centile val-
ues. To test for differences across comparison groups in categorical
data, we used Fisher’s exact test and for continuous data, used the
Wilcoxon rank-sum test for two-sample testing and Kruskal-Wallis
where there were more than 2 groups. Analysis of symptom co-
occurrence was done using the Jaccard similarity index and repre-
sented visually as heatmaps with dendrograms constructed from
complete hierarchical clustering results (where 0 is no co-occurrence
and 1 is perfect co-occurrence). We then identified clusters of symp-
toms based upon the hierarchical dendrograms and clusters that
were seen on the heatmap.
For disability, breathlessness, and EQ5D-5L index (health state),
we calculated the change in value reported by participants before
onset of their Covid-19 illness compared to the follow up assessment.
For health state at the follow up assessment, we used the EQ5D-5L
with the English standardised valuation study protocol (EQ-VT) value
set, developed by the EuroQol group on the composite time trade-off
(cTTO) valuation [27]. Overall changes in summary health index,
before and after Covid-19 onset, were summarised for the cohort
using the Paretian Classification of Health Change (PCHC) method
[28,29]. Summary EQ5D-5L indices and change in summary EQ5D-5L
index were measured on a scale of 0 to 1, with 1 being perfect health
and 0 being worst health imaginable. We calculated both the overall
estimates and estimates for individual EQ5D-5L dimensions. As a sen-
sitivity analysis, to identify the impact of the presence of a positive
SARS-CoV-2 PCR test, we excluded those participants who did not
have a positive PCR test reported. We then looked at the outcomesfrom UK hospitals after Covid-19: A prospective, multicentre cohort
Lancet Regional Health - Europe (2021), https://doi.org/10.1016/j.
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ensure there was no change in the direction or magnitude of the
effect.
We created models to adjust for age, sex, presence of comorbid-
ities and in-hospital severity of Covid-19, according to the maximum
level of respiratory support that was required. Multilevel logistic
regression was used for binary outcomes, and linear regression mod-
els were used for continuous outcomes. In both model types, we
adjusted for the effects of explanatory variables using fixed-effects
and centre by including a random-effects term. For all models, vari-
able selection was performed based on clinical plausibility, and final
models were selected based on clinical relevance guided by minimi-
sation of the Akaike information criterion (AIC). Variables were only
included in the model if they were present during the first hospital
admission for Covid-19. All models were checked for first order inter-
actions and any meaningful interactions were retained and incorpo-
rated as dummy variables. Effect estimates are presented as odds
ratios for binary outcomes or mean differences for continuous out-
comes, alongside the corresponding 95% confidence interval (95% CI).
Statistical analyses were performed using R version 3.6.3 (R Founda-
tion for Statistical Computing, Vienna, AUT) with the tidyverse, final-
fit, eq5d and Hmisc packages. Statistical significance was taken at the
level of P  0.05.2.6. Public and patient involvement
This was an urgent public health research study in response to a
public health emergency of international concern. Patients and the
public were therefore not involved in the design, of the acute phase
rapid response research. However, patients and people living with
long Covid were involved in the design, conduct and interpretation of
the follow up study. The follow up data collection survey and associ-
ated patient information was informed by the founding members of
the Long Covid support group, who themselves are living with long
Covid. The survey was also piloted in several settings in the UK with
patients affected by Covid-19 from different demographics, and feed-
back incorporated into the final version. This included suggestions on
the data on symptoms collected and the way questions were asked as
well as on the patient information. The results and interpretation of
the findings and final manuscript were informed by members of the
Long Covid support group.2.7. Role of the funding source
The study sponsors and funders had no role in the study design,
collection, analysis, interpretation of data, writing of the report, or
the decision to submit the article for publication. Investigators were
independent from funders and the authors have full access to all
of the data, including any statistical analysis and tables.3. Results
Of the 2150 eligible people in the CCP-UK study who were dis-
charged from their acute admission alive, 401% (862/2150) provided
consent to be contacted for follow-up. Of these, 978% (843/862)
were contacted. From these 843 people, 977% (824/843) were 18 or
over and 537% (443/824) completed the follow-up questionnaire.
Finally, of respondents 738% (327/443) responded 90 days or more
after symptom onset. Included participants completed the follow-up
questionnaire through self-assessment (71¢6% 234/327), telephone
(24¢5% 80/327) or in outpatient clinic (4¢0% 13/327, Fig. 1). The
median follow-up time from symptom onset was 222 days (IQR: 189
to 269 days, range: 112 to 343 days, Table 1).Please cite this article as: L. Sigfrid et al., Long Covid in adults discharged
study using the ISARIC WHO Clinical Characterisation Protocol, The
lanepe.2021.1001863.1. Participant characteristics
Table 1 shows the characteristics of participants who responded.
The majority of participants were male (58¢7%, 192/327), with a
median age of 59¢7 (25th centile 51.7 to 75th centile 67¢7) years and
of white ethnicity (81¢0%, 265/327, Table 1). Asthma (19¢9%, 65/327)
and diabetes (19¢0%, 62/327) were the most common comorbidities
(Table 1). 281% (92/327) received invasive mechanical ventilation.
Compared with the study population who were contacted and did
not respond, respondents were significantly more likely to be of
white ethnicity (81¢0%, 265/327 participants versus 66¢6%, 331/544 of
non-respondents), were more likely to be ex-smokers (28¢1%, 92/327
participants versus 24¢7% 123/497 of non-respondents) and were
more likely to have been admitted to critical care (39¢8% 130/327 in
participants versus 26¢8% 133/497 in non-respondents,
Supplementary Table 1).
3.2. Outcomes and symptoms
Of 327 participants, 54¢7% (179/327) did not feel they had fully
recovered at the time of follow-up. At the univariable level, there
were no associations between not feeling recovered and the risk fac-
tors of age, sex, ethnicity, and comorbidities (Table 1) but we found
patients with a higher severity of acute disease were significantly
more likely not to feel recovered. Persistent or new symptoms were
reported by 93¢3% (305/327) participants (Table 2). The most fre-
quently reported symptoms were fatigue 82¢8% (255/308), shortness
of breath 53¢5% (175/327), and problems sleeping 46¢2% 151/327,
Fig. 2A).
A heatmap and dendrogram of symptom co-occurrence identified
two major clusters of symptoms (Fig. 2B); a fatigue, myalgia and sen-
sorineural deficits cluster and an olfactory, appetite and urinary clus-
ter (loss of smell, loss of taste, difficulty passing urine, weight loss
and loss of appetite). Within the fatigue, myalgia and sensorineural
deficits cluster, there was a distinct minor cluster affecting move-
ment (muscle pain, joint pain, balance and limb weakness).
In addition to symptomatic breathlessness, 46¢8% (153/327) of
participants reported increased breathlessness compared to their
pre-Covid-19 baseline. Overall, change in breathlessness was not
affected by age or number of comorbidities (Fig. 3), but was signifi-
cantly higher in females compared to males (41¢7%, 80/192 in males
versus 54¢1% 73/135 in females). Of participants with a pre-Covid-19
MRC grade 1, 34¢0% (73/215) reported an increase to grade 2, and
25¢6% (55/213) reported an increase to grades 3-5 at time of post hos-
pital follow-up (Fig. 4A to 4C). Proportionally, those who were admit-
ted to critical care were more likely to have a higher MRC dyspnoea
grade at the time of post hospital follow-up.
Overall, intensity of fatigue was unrelated to age or disease sever-
ity in hospital (Fig. 3, Table 2), but females were found to have signifi-
cantly increased levels of fatigue compared with males (median
fatigue 0-10 VAS score, males 4¢0, IQR 2.0 to 6; versus females 6¢0,
IQR 2¢0 to 7¢0, Supplementary Table 2, Supplementary Figure 1).
New or worsened disability in at least one Washington Group
domain was experienced by 24¢2% (79/327). This did not change by
in-hospital Covid-19 severity (Table 2) or comorbidities (Fig. 3).
Females reported a greater number of new or worsened disabilities
compared to males (20¢3%, 39/192 in males compared with 29¢6%,
40/135 in females, Supplementary Table 2). The most affected
domain was walking and mobility (33¢3% 109/327 new mild or wors-
ened disability, 6¢4% 21/327 new moderate or worsened disability
and 0¢3% 1/327 new severe or worsened disability,
Supplementary Table 3), followed by memory and concentration
(30¢0% 90/327 new mild or worsened disability, 9.8% 32/327 new
moderate or worsened disability). There were significant differences
in domains affected by sex, with females reporting significantly
higher levels of visual disabilities (12¢0% 23/192 new mild or
from UK hospitals after Covid-19: A prospective, multicentre cohort
Lancet Regional Health - Europe (2021), https://doi.org/10.1016/j.
Fig. 1. Patient inclusion flowchart
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ened disability for females, Supplementary Table 3), higher levels of
walking disability (28.6% 55/192 new mild or worsened disability for
males versus 40¢0% 54/135 new or worsened mild disability for
females; 5¢6% 11/192 new moderate or worsened disability for males
versus 7¢4% 10/327 newmoderate or worsened disability for females)
and memory disability (27¢1% 52/192 new mild or worsened disabil-
ity for males versus 34¢1% 46/135 new mild or worsened disability
for females; 7¢3% 14/192 new moderate or worsened disability for
males versus 13¢3% 18/135 new moderate or worsened disability for
females, Supplementary Table 4).
Overall summary EQ5D-5L index was 10% lower overall following
Covid-19 (median difference -0¢1 points, -0¢2 25th centile to 0¢0 75th
centile, Table 2). This change was independent of age or comorbid-
ities (Fig. 3). The EQ5D-5L dimensions for which most participantsPlease cite this article as: L. Sigfrid et al., Long Covid in adults discharged
study using the ISARIC WHO Clinical Characterisation Protocol, The
lanepe.2021.100186reported worsening were usual activities (38¢9%, 121/311), anxiety/
depression (37¢6%, 117/311), and pain/discomfort (37¢6%, 117/311)
(Supplementary Table 5). Female sex was significantly associated
with increased problems in the usual activity, pain or discomfort and
anxiety and depression domains (Supplementary Table 6).
3.3. Predictors of long-term Covid-19 outcomes
Using multilevel regression models, we adjusted for the effects
of age by sex (as this was identified as a significant interaction
and retained in our models), the presence of comorbidity and ini-
tial in-hospital severity of Covid-19. This generated 6 groups;
Males under 50 (34/327), males between 50 and 69 (114/327),
males 70 and over (44/327), females under 50 (36/327), females
between 50 and 69 (81/327), and females 70 and over (18/327).from UK hospitals after Covid-19: A prospective, multicentre cohort
Lancet Regional Health - Europe (2021), https://doi.org/10.1016/j.
Table 1
Characteristics of participants who responded
Recovered or unsure Does not feel fully recovered (Missing) p-value
Total N (%) 144 (44
0)
179 (54¢7) 4 (1¢2)
Age Median (IQR) 60¢5 (53¢2 to 69.8) 59¢4 (50¢3 to 66¢7) 54¢2 (48¢2 to 58¢5) 0¢089
Under 50 26 (37¢1) 43 (61¢4) 1 (1¢4)
50 to 69 83 (42¢6) 109 (55¢9) 3 (1¢5)
Over 70 35 (56¢5) 27 (43¢5) 0 (0¢0)
Sex at Birth Male 87 (45¢3) 103 (53¢6) 2 (1¢0) 0¢683
Female 57 (42¢2) 76 (56¢3) 2 (1¢5)
Ethnicity White 115 (43¢4) 147 (55¢5) 3 (1¢1) 0¢206
South Asian 2 (25¢0) 6 (75¢0) 0 (0¢0)
East Asian 3 (75¢0) 1 (25¢0) 0 (0¢0)
Black 10 (66¢7) 5 (33¢3) 0 (0¢0)
Other Ethnic Minority 10 (47¢6) 10 (47¢6) 1 (4¢8)
(Missing) 4 (28¢6) 10 (71¢4) 0 (0¢0)
Smoking Never Smoked 84 (47¢7) 90 (51¢1) 2 (1¢1) 0¢892
Current Smoker 4 (57¢1) 3 (42¢9) 0 (0¢0)
Former Smoker 43 (46¢7) 47 (51¢1) 2 (2¢2)
(Missing) 13 (25¢0) 39 (75¢0) 0 (0¢0)
Diabetes No 112 (44¢1) 138 (54¢3) 4 (1¢6) 0¢972
Yes 27 (43¢5) 35 (56¢5)
Obesity (as defined by clinical staff) No 116 (45¢7) 136 (53¢5) 2 (0¢8) 0¢291
Yes 20 (35¢7) 34 (60¢7) 2 (3¢6)
(Missing) 8 (47¢1) 9 (52¢9) 0 (0¢0)
Chronic cardiac disease No 119 (43¢8) 149 (54¢8) 4 (1¢5) 1¢000
Yes 20 (45¢5) 24 (54¢5) 0 (0¢0)
(Missing) 5 (45¢5) 6 (54¢5) 0 (0¢0)
Chronic pulmonary disease (not asthma) No 126 (43¢4) 160 (55¢2) 4 (1¢4) 0¢592
Yes 12 (52¢2) 11 (47¢8) 0 (0¢0)
(Missing) 6 (42¢9) 8 (57¢1) 0 (0¢0)
Asthma (physician diagnosed) No 114 (45¢2) 135 (53¢6) 3 (1¢2) 0¢410
Yes 25 (38¢5) 39 (60¢0) 1 (1¢5)
(Missing) 5 (50¢0) 5 (50¢0) 0 (0¢0)
Chronic kidney disease No 131 (44¢0) 163 (54¢7) 4 (1¢3) 1¢000
Yes 8 (44¢4) 10 (55¢6) 0 (0.0)
(Missing) 5 (45¢5) 6 (54¢5) 0 (0¢0)
Malignant neoplasm No 136 (44¢4) 166 (54¢2) 4 (1¢3) 1¢000
Yes 4 (40¢0) 6 (60¢0) 0 (0¢0)
(Missing) 4 (36¢4) 7 (63¢6) 0 (0¢0)
Rheumatologic disorder No 131 (45¢2) 155 (53¢4) 4 (1¢4) 0¢334
Yes 8 (33¢3) 16 (66¢7) 0 (0¢0)
(Missing) 5 (38¢5) 8 (61¢5) 0 (00)
ISARIC4C Mortality Score (predicted in
hospital mortallity)
Median (IQR) 7¢0 (5¢0 to 9¢0) 6¢0 (4¢0 to 9¢0) 5¢5 (5¢0 to 6¢0) 0¢648
Severity Scale 3 (did not receive supplemental
oxygen)
34 (50¢0) 33 (48¢5) 1 (1¢5) 0¢001
Scale 4 (received supplemental oxygen) 63 (53¢4) 53 (44¢9) 2 (1¢7)
Scale 5 (received HFNC or NIV) 22 (44¢9) 27 (55¢1) 0 (0¢0)
Scale 6 or 7 (received invasive mechani-
cal ventilation or critical care)
25 (27¢2) 66 (71¢7) 1 (1¢1)
Critical care admission Ward level care only 99 (50¢3) 96 (48¢7) 2 (1¢0) 0¢008
Admitted to Critical Care 45 (34¢6) 83 (63¢8) 2 (1¢5)
Length of stay (days) Median (IQR) 8¢0 (5¢0 to 13¢0) 11¢0 (6¢2 to 25¢0) 4¢5 (3¢0 to 7¢8) <0¢001
Time from symptoms to completing sur-
vey (days)
Median (IQR) 221¢0 (190¢0 to 245¢0) 224¢0 (188¢0 to 292¢0) 210¢0 (194¢2 to 218.¢5) 0¢419
Time from discharge to completing sur-
vey (days)
Median (IQR) 200¢0 (177¢0 to 230¢0) 199¢0 (161¢0 to 268¢0) 195¢0 (178¢0 to 208¢2) 0¢846
HFNC  High flow nasal cannulae, NIV  Noninvasive ventilation, IQR  Interquartile range, presented as 25th to 75th centiles. Numbers are presented as N (%), unless otherwise
denoted as a continuous variable.
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females under 50 were 5 times less likely to feel fully recovered
(Fig. 4). Similarly, those who received invasive mechanical venti-
lation were 3¢6 times less likely to feel fully recovered (Fig. 4).
For the secondary outcomes, age did not appear to be associated
with better or worse long-term outcomes (Table 3). Females
under 50 were more likely than men to experience persistent
fatigue and seven times more likely to experience greater breath-
lessness, twice as likely to develop new disability and had a sig-
nificantly poorer health state (EQ5D-5L), all of which persisted in
adjusted analyses (Table 3). Participants with one or morePlease cite this article as: L. Sigfrid et al., Long Covid in adults discharged
study using the ISARIC WHO Clinical Characterisation Protocol, The
lanepe.2021.100186comorbidities were more likely to experience greater fatigue, dis-
ability, and a poorer health state (EQ5D-5L, Table 3).
To explore these findings further, we then looked to see if there
were any differences in comorbidity or in-hospital disease severity
by sex. We found males were significantly more likely to have greater
comorbidity (Supplementary Table 8) and more severe in hospital
disease (Supplementary Table 9).When we performed a sensitivity
analysis for our overall findings, this time excluding patients who did
not have a positive SARS-CoV-2 PCR test. The results of these sensitiv-
ity analyses (Supplementary Tables 10 and 11), show no effect of
SARS-CoV-2 positivity on our estimates for long-term outcomes.from UK hospitals after Covid-19: A prospective, multicentre cohort
Lancet Regional Health - Europe (2021), https://doi.org/10.1016/j.
Table 2
Long-term outcomes by severity of acute Covid-19




Scale 5 (received HFNC
or NIV)





Total N (%) 68 (20¢8) 118 (36¢1) 49 (15¢0) 92 (28¢1)
Self-reported overall
recovery
Feels fully recovered 21 (30¢9) 34 (28¢8) 11 (22¢4) 17 (18¢5) 0¢006
Does not feel fully
recovered
33 (48¢5) 53 (44¢9) 27 (55¢1) 66 (71¢7)
Not sure 13 (19¢1) 29 (24¢6) 11 (22¢4) 8 (8¢7)
(Missing) 1 (1¢5) 2 (1¢7) 0 (0¢0) 1 (1¢1)
New or persistent
symptoms
No new or persistent
symptoms
3 (4¢4) 9 (7¢6) 6 (12¢2) 4 (4¢3) 0¢268
New or persistent
symptoms




No change 25 (36¢8) 55 (46¢6) 20 (40¢8) 27 (29¢3) 0¢062
Less breathless 2 (2¢9) 5 (4¢2) 2 (4¢1) 2 (2¢2)
More breathless 32 (47¢1) 41 (34¢7) 24 (49¢0) 56 (60¢9)
(Missing) 9 (13¢2) 17 (14¢4) 3 (6¢1) 7 (7¢6)
Fatigue level (0 to 10
VAS)




Median (IQR) -0¢1 (-0¢2 to 0¢0) -0¢0 (-0¢1 to 0¢0) -0.1 (-0¢2 to 0¢0) -0¢1 (-0¢3 to -0¢0) 0¢004
Washington Group
Short Set
No change in disability 52 (76¢5) 88 (74¢6) 35 (71¢4) 66 (71¢7) 0¢892
New or worse 15 (22¢1) 27 (22¢9) 13 (26¢5) 24 (26¢1)
(Missing) 1 (1¢5) 3 (2¢5) 1 (2¢0) 2 (2¢2)
HFNC  High flow nasal cannulae, NIV  Noninvasive ventilation, MRC  Medical Research Council, IQR  Interquartile range, presented as 25th to 75th centiles. Numbers
are presented as N (%), unless otherwise denoted as a continuous variable.
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We found high rates of long-term symptoms and poor long-term
outcomes, which were present several months after hospitalisation
for Covid-19. This has implications for planning of care and rehabilita-
tion pathways. These patients may present to multiple specialitiesFig. 2. Proportion of new or persistent symptoms occurring (Fig. 2A) and their co-occurrence
For Figure 2A, fatigue is coloured in green as this outcome was derived from the fatigue
presence of the fatigue symptom (see Supplementary Table 7 for raw values). Erectile dysfun
for any sex. For Figure 2B, the Jaccard similarity index was calculated and presented as intens
co-occurring.
Please cite this article as: L. Sigfrid et al., Long Covid in adults discharged
study using the ISARIC WHO Clinical Characterisation Protocol, The
lanepe.2021.100186within the health care system unless coordinated by a dedicated long
Covid service. The range of syndromes identified highlights a need for
long Covid clinics to triage patients for further comprehensive diag-
nostics, based on symptom cluster, including specialist imaging, for
assessing underlying aetiology to inform treatment and improve out-
comes. Females under 50, and those with severe acute diseasewith each other (Fig. 2B).
visual analogue outcome, where a fatigue rating of 2 or greater was considered as the
ction affected 23¢4% (45/192) of males included, not shown as Figure 2A presents data
ity of red colour, with 0 (white) being no co-occurrence and 1 (bright red) being always
from UK hospitals after Covid-19: A prospective, multicentre cohort
Lancet Regional Health - Europe (2021), https://doi.org/10.1016/j.
Fig. 3. Outcomes stratified by age and presence of one or more comorbidities.
Figure 3A  Proportion of participants not feeling fully recovered; Figure 3B  Proportion of participants with new or persistent symptoms; Figure 3C - Proportion of partici-
pants with increased breathlessness as measured by MRC dyspnoea scale; Figure 3D  Participant rated fatigue on 0 to 10 VAS; Figure 3E  Change in overall EQ5D-5L summary
health index; Figure 3F  presence of new or worse disability in at least one Washington Group disability domain. Point estimates presented alongside 95% confidence intervals.
MRC Medical Research Council, VAS  Visual Analogue Scale.
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adjusting for severity of the initial illness. Interestingly, our findings
were largely unaffected by existing patient comorbidities or disability.
Our findings add considerably to the current literature, as we iden-
tify the main risk factor for worse long-term outcomes are being
female and under the age of 50. We also have been able to quantify
the significant deterioration in disability and breathlessness-related
disability in detail. The range of symptoms reported include those
which may be related to direct lung damage, such as breathlessness,
and also those for which an underlying pathophysiological mechanism
may be less clear such as fatigue, muscle pain and cognitive com-
plaints. The latter group are also features of other post infectious syn-
dromes and post intensive care syndrome, and may have a similar
aetiology, such as infection triggered autoimmunity, dysautonomia or
other mechanism [6-10]. Our study did not make laboratory measure-
ments or collect biological samples as part of the follow-up and hence
is not designed to elucidate mechanisms. Future studies which do this
will be key to identifying relevant therapeutic targets in long-Covid.
Many of our findings are largely in agreement with other recent
studies in other populations globally, which also found high rates of
breathlessness and fatigue [4,5]. In the community setting, a recent
mobile application-based study, described very high rates of breath-
lessness (71%) and fatigue (98%) in those reporting symptoms persist-
ing over 28 days [2]. Interestingly, in our population, the presence of
symptoms many months after initial infection are higher than thePlease cite this article as: L. Sigfrid et al., Long Covid in adults discharged
study using the ISARIC WHO Clinical Characterisation Protocol, The
lanepe.2021.10018676% reported by Huang et al. and three times higher than that
reported by Munblit et al. There are several reasons why we have
found higher rates, which could be related to those responding to
each study, or the severity of disease across the different study popu-
lations. The Huang et al. and Munblit et al. studies included very
small numbers of patients requiring critical care or mechanical venti-
lation (1% in Huang et al. and under 2¢6% in Munblit et al, in contrast
to 28¢1% 92/327 in our study), suggesting there are significant differ-
ences between these populations and our study population; Survi-
vors of general critical illness, independent of baseline disease, may
experience persistent breathlessness, fatigue, muscle weakness, and
other symptoms of post-intenisve care syndrome which cause sub-
stantial decifits in quality of life that may persist for many years [10].
There may several reasons for this difference in study population,
such as challenges to recruitment of critically unwell patients, differ-
ing in-hospital mortality rates, preexisting population comorbidities
or pressure on the healthcare systems during the pandemic. Based on
data from several countries, the higher rates of participants requiring
critical care in our study suggests our data is likely to be more gener-
alisable [3033].
In our study, being young, female and having a high severity of
acute disease were the strongest independent predictors of poor
long-term outcomes. It is unclear why females had the worst out-
comes. This could be to do with the effects of initial exposure, where
females are more likely to be in industries where exposure to SARS-from UK hospitals after Covid-19: A prospective, multicentre cohort
Lancet Regional Health - Europe (2021), https://doi.org/10.1016/j.
Fig. 4. MRC Dyspnoea scale prior to Covid-19 onset and at the time of follow-up.
Figure 4A  MRC dyspnoea scale reported prior to onset of Covid-19 symptoms;
Figure 4B  MRC dyspnoea scale at the time of follow-up; Figure 4C  Alluvial plot of
proportion of the changes in proportion of males and females in each MRC scale grade
before symptom onset and at time of follow-up, stratified in each sex group by admis-
sion to critical care. In Figure 4C, for females, there are greater numbers of participants
who begin at MRC 1 and transition to higher levels on the scale compared with males.
MRC Medical Research Council
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L. Sigfrid et al. / The Lancet Regional Health - Europe 00 (2021) 100186 9CoV-2 may be higher [34], however recent data suggests teachers do
not have greater exposure than other working-age populations and
there is emerging evidence of divergent host responses to SARS-CoV-
2 infection [35,36]. Another explanation is that females are more
likely to survive severe acute disease than men, so could have worse
long-term outcomes as a result. However, in our data, we could not
find any differences by sex across several measures of disease sever-
ity. A further possibility is that men felt less able or inclined to dis-
close symptoms. There is some discussion in the literature that recall
bias, and also reporting of symtoms may differ between males and
females, which may account for some of the gender difference seen 
however this would not account for these differences being also
related to age as well as gender [37]. From our findings it is clear
more research is required into why females have worse long-term
outcomes, particularly as sectors where females are likely to have
greater exposure to SARS-CoV-2 are beginning to reopen (e.g. educa-
tion, hospitality and healthcare).
There are several limitations to our study. First, we were not able
to follow all the cases that were discharged from hospital, either
because they did not give permission or because they did not respond
to repeated requests for information. We attempted to reach non-
responders to the survey via telephone follow-up to limit potential
for selection bias, but not all could be reached. However the 73%
response rate is substantially above the expected response rate for
multi-modal questionaires (60%) [38]. It is possible that those who
did not respond might have been well and therefore uninterested in
responding, but it could also be that some were too unwell to
respond, had died or moved away. Our results may therefore not be
fully representative of the entire population of those hospitalised
with Covid-19. The potential completion bias may have led to over
representation of the prevalence of people affected by long Covid,
but may also be underrepresenting people from different demo-
graphics. Nevertheless, the data shows that amongst the cohort of
people that consented to be contacted post Covid-19 hospital dis-
charge, a large proportion were not fully recovered from Covid more
than three months post discharge. This is similar to what has been
reported in other countries [4,5].
Secondly, we did not include patients hospitalised with other
non-Covid-19 illness or a contemporaneous control group, therefore
it is unknown if the changes in our outcomes e.g. quality of life, are
specific to recovery from Covid-19 or may be linked to other aspects
of life during the pandemic. The study used to generate this data (ISA-
RIC WHO Clinical Characterisation Protocol/CCP-UK) is a prospective
pandemic preparedness protocol which is agnostic to disease and has
a pragmatic design to allow recruitment during pandemic conditions.
Thirdly, patients only completed the survey at one timepoint, limiting
comparison across repeat measures. This also meant retrospective
measures asking patients to rate outcomes before their Covid-19 ill-
ness were included, which are open to recall bias. Fourth, the differ-
ences in collecting data (in clinic, by post, by telephone) may add to
heterogeneity in the data. Finally, as our study focussed on hospital-
ised patients primarily from the first wave of infection in the UK, our
data cannot be generalised to those with disease managed in the
community who comprise the majority of individuals affected by
Covid-19.
Future research should focus on establishing the optimal care of
this cohort, identifying interventions to test in randomised trials and
to identify the mechanisms underlying adverse long-term outcomes.
The PHOSP-Covid (Post-HOSPitalisation Covid-19) study is ongoing
and will inform patient care by adding to our data on the long-term
sequelae of Covid-19, looking at the impact on these of acute and
post-discharge interventions, and exploring possible mechanisms
including measurement of laboratory parameters and functional
diagnostics [39].from UK hospitals after Covid-19: A prospective, multicentre cohort
Lancet Regional Health - Europe (2021), https://doi.org/10.1016/j.
Fig. 5. Multilevel model for primary outcome of self-reported recovery
(reference level is feeling fully recovered)
Table 3
Multilevel regression models for secondary outcomes of new or persistent symptoms, change in MRC dyspnoea scale, fatigue, EQ5D-5L summary index change
andWashington Short Set new or worse disability.














Set new or worse
disability: OR (95%
Confidence Interval)
Sex at Birth by Age Male | Under 50 - - - - -




0¢44 (-0¢56 to 1¢44,
p=0¢194)








0¢38 (-0¢84 to 1¢60,
p=0¢272)




























0¢29 (-1¢33 to 1¢92,
p=0¢362)











0¢95 (0¢35 to 1¢55,
p=0¢001)




Severity Scale 3 (did not
receive supple-
mental oxygen)








-0¢26 (-1¢06 to 0¢55,
p=0¢266)










-0¢20 (-1¢22 to 0¢83,
p=0¢354)













-0¢18 (-1¢09 to 0¢74,
p=0¢354)




HFNC  High flow nasal cannulae, NIV  Noninvasive ventilation, MRC  Medical Research Council. Model metrics: For persistent symptoms - Number in
model = 327, Number of groups = 32, AIC = 172¢4, C-statistic = 0¢683; For change in MRC dyspnoea level - Number in model = 291, Number of groups = 32,
AIC = 383.1, C-statistic = 0.767; For change in fatigue - Number in model = 308, Number of groups = 32, Log likelihood = -724¢13, REML criterion = 1448¢3; For
change in health state (EQ5D-5L) - Number in model = 311, Number of groups = 32, Log likelihood = 80¢55, REML criterion = -1611; For change in Washington
short set disability - Number in model = 320, Number of groups = 31, AIC = 355¢1, C-statistic = 0¢74.
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In our study of 327 patients who were discharged alive from hos-
pital, we found most participants reported symptoms months after
acute Covid-19 infection. The most common symptoms were fatigue
and breathlessness. Participants reported significant difficulties,
including increased breathlessness, new or worsened disability and
worse quality of life following Covid-19. These symptoms were
largely independent of age and prior comorbidity, suggesting that
the long-term effects of Covid-19 are determined by factors that dif-
fer from those that predict increased mortality. Moreover, the high
frequency and severity of long-term symptoms emphasise the impor-
tance of long-Covid symptoms and the potential long-term impact on
population health and wellbeing. The data highlights an urgent needPlease cite this article as: L. Sigfrid et al., Long Covid in adults discharged
study using the ISARIC WHO Clinical Characterisation Protocol, The
lanepe.2021.100186for access to comprehensive assessments for people living with long
Covid, including complex diagnostics to identify aetiology and inform
appropriate treatment to improve long term Covid-19 outcomes.
^ISARIC Global Covid-19 follow up working group:
Adam Ali, John H Amuasi, Andrea Angheben, John Kenneth Baille,
Valeria Balan, Ibrahim Richard Bangura, Anna Beltrame, Frank Bloos,
Lucille Blumberg, Fernando Bozza, Danilo Buonsenso, Caterina Cami-
niti, Gail Carson, Daniel Cassaglia, Muge Cevik, Allegra Chatterjee,
Andrew Dagens, Yash Doshi, Thomas M. Drake, Murray Dryden, Anne
Margarita Dyrhol Riise, Michael Edelstein, Rob Fowler, Kyle Gomez,
Katrina Hann, Ewen M Harrison, Madiha Hashmi, Lars Hegelund,
Aquiles Henriquez Trujillo, Antonia Ho, Jan Cato Holter, Jane Ireson,
Nina Jamieson, Waasila Jassat, Edwin Jesudason, Anders Benjaminfrom UK hospitals after Covid-19: A prospective, multicentre cohort
Lancet Regional Health - Europe (2021), https://doi.org/10.1016/j.
ARTICLE IN PRESS
JID: LANEPE [m5G;August 6, 2021;1:41]
L. Sigfrid et al. / The Lancet Regional Health - Europe 00 (2021) 100186 11Kildal, Sulaiman Lakoh, Nicola Latronico, James Lee, Wei Shen Lim,
Sam Lissaeur, Nazir Lone, David J Lowe, Sinnadurai Manohan, Romans
Matulevics, Joanne McPeake, Laura Merson, Roberta Meta, Melina
Michelen, Sarah Moore, Ben Morton, Caroline Mudara, Daniel Mun-
blit, Srinivas Murthy, Behzad Nadjm, Ebrahim Ndure, Nikita Nekliu-
dov, Piero Olliaro, Carlo Palmieri, Prasan K Panda, Simone Piva,
Daniel R Plotkin, Matteo Puntini, Jordi Rello, Liliana Resende, Luis
Felipe Reyes, Ishmeala Rigby, Sergio Ruiz Saltana, Clark D Russell,
Steffi Ryckaert, Janet T Scott, Malcolm G. Semple, Louise Sigfrid, Girish
Sindhwani Pulm, Arne Søraas, Renaud Tamisier, Lance Turtle, Caro-
line Vika, Natalie Wright
^^ISARIC4C investigators Consortium lead investigator:
J Kenneth Baillie, Malcolm G Semple, Peter JM Openshaw; Gail
Carson, Benjamin Bach, Wendy S Barclay, Debby Bogaert, Meera
Chand, Graham S Cooke, Annemarie B Docherty, Jake Dunning, Ana
da Silva Filipe, Tom Fletcher, Christoper A Green, Ewen M Harrison,
Julian A Hiscox, Antonia Ying Wai Ho, Peter W Horby, Samreen Ijaz,
Saye Khoo, Paul Klenerman, Andrew Law, Wei Shen Lim, Alexander J
Mentzer, Laura Merson, Alison M Meynert, Mahdad Noursadeghi,
Shona C Moore, Massimo Palmarini, William A Paxton, Georgios Pol-
lakis, Nicholas Price, Andrew Rambaut, David L Robertson, Clark D
Russell, Vanessa Sancho-Shimizu, Janet T Scott, Thushan de Silva,
Louise Sigfrid, Tom Solomon, Shiranee Sriskandan, David Stuart,
Charlotte Summers, Richard S Tedder, Emma C Thomson, AA Roger
Thompson, Ryan S Thwaites, Lance CW Turtle, Rishi K Gupta, Carlo
Palmieri, Maria Zambon, Chloe Donohue, Ruth Lyons, Fiona Griffiths,
Wilna Oosthuyzen, Riinu Pius, Thomas M Drake, Cameron J Fairfield,
Stephen R Knight, Kenneth A Mclean, Derek Murphy, Catherine A
Shaw, Michelle Girvan, Egle Saviciute, Stephanie Roberts, Janet Harri-
son, Laura Marsh, Marie Connor, Sophie Halpin, Clare Jackson, Carrol
Gamble, Andrew Law, Murray Wham, Sara Clohisey, Ross Hendry,
James Scott-Brown, Victoria Shaw, Sarah E McDonald, Jane A Arm-
strong, Milton Ashworth, Innocent G Asiimwe, Siddharth Bakshi,
Samantha L Barlow, Laura Booth, Benjamin Brennan, Katie Bullock,
Benjamin WA Catterall, Jordan J Clark, Emily A Clarke, Sarah Cole,
Louise Cooper, Helen Cox, Christopher Davis, Oslem Dincarslan, Chris
Dunn, Philip Dyer, Angela Elliott, Anthony Evans, Lorna Finch, Lewis
WS Fisher, Terry Foster, Isabel Garcia-Dorival, William Greenhalf, Phi-
lip Gunning, Catherine Hartley, Rebecca L Jensen, Christopher B Jones,
Trevor R Jones, Shadia Khandaker, Katharine King, Robyn T. Kiy,
Chrysa Koukorava, Annette Lake, Suzannah Lant, Diane Latawiec, Lara
Lavelle-Langham, Daniella Lefteri, Lauren Lett, Lucia A Livoti, Maria
Mancini, Sarah McDonald, Laurence McEvoy, John McLauchlan, Soe-
ren Metelmann, Nahida S Miah, Joanna Middleton, Joyce Mitchell,
Shona C Moore, Ellen G Murphy, Rebekah Penrice-Randal, Jack Pil-
grim, Tessa Prince, Will Reynolds, P. Matthew Ridley, Debby Sales,
Victoria E Shaw, Rebecca K Shears, Benjamin Small, Krishanthi S Sub-
ramaniam, Agnieska Szemiel, Aislynn Taggart, Jolanta Tanianis-
Hughes, Jordan Thomas, Erwan Trochu, Libby van Tonder, Eve Wil-
cock, J. Eunice Zhang, Lisa Flaherty, Nicole Maziere, Emily Cass, Ale-
jandra Doce Carracedo, Nicola Carlucci, Anthony Holmes, Hannah
Massey, Nicola Wrobel, Sarah McCafferty, Kirstie Morrice, Alan
MacLean, Daniel Agranoff, Ken Agwuh, Dhiraj Ail, Erin L. Aldera, Ana
Alegria, Brian Angus, Abdul Ashish, Dougal Atkinson, Shahedal Bari,
Gavin Barlow, Stella Barnass, Nicholas Barrett, Christopher Bassford,
Sneha Basude, David Baxter, Michael Beadsworth, Jolanta Bernato-
niene, John Berridge, Nicola Best, Pieter Bothma, David Chadwick,
Robin Brittain-Long, Naomi Bulteel, Tom Burden, Andrew Burten-
shaw, Vikki Caruth, David Chadwick, Duncan Chambler, Nigel Chee,
Jenny Child, Srikanth Chukkambotla, Tom Clark, Paul Collini, Cather-
ine Cosgrove, Jason Cupitt, Maria-Teresa Cutino-Moguel, Paul Dark,
Chris Dawson, Samir Dervisevic, Phil Donnison, Sam Douthwaite,
Ingrid DuRand, Ahilanadan Dushianthan, Tristan Dyer, Cariad Evans,
Chi Eziefula, Chrisopher Fegan, Adam Finn, Duncan Fullerton, Sanjeev
Garg, Sanjeev Garg, Atul Garg, Effrossyni Gkrania-Klotsas, Jo Godden,
Arthur Goldsmith, Clive Graham, Elaine Hardy, Stuart Hartshorn,Please cite this article as: L. Sigfrid et al., Long Covid in adults discharged
study using the ISARIC WHO Clinical Characterisation Protocol, The
lanepe.2021.100186Daniel Harvey, Peter Havalda, Daniel B Hawcutt, Maria Hobrok, Luke
Hodgson, Anil Hormis, Michael Jacobs, Susan Jain, Paul Jennings, Agi-
lan Kaliappan, Vidya Kasipandian, Stephen Kegg, Michael Kelsey,
Jason Kendall, Caroline Kerrison, Ian Kerslake, Oliver Koch, Gouri
Koduri, George Koshy, Shondipon Laha, Steven Laird, Susan Larkin,
Tamas Leiner, Patrick Lillie, James Limb, Vanessa Linnett, Jeff Little,
Mark Lyttle, Michael MacMahon, Emily MacNaughton, Ravish Man-
kregod, Huw Masson, Elijah Matovu, Katherine McCullough, Ruth
McEwen, Manjula Meda, Gary Mills, Jane Minton, Mariyam Mirfen-
deresky, Kavya Mohandas, Quen Mok, James Moon, Elinoor Moore,
Patrick Morgan, Craig Morris, Katherine Mortimore, Samuel Moses,
Mbiye Mpenge, Rohinton Mulla, Michael Murphy, Megan Nagel, Tha-
pas Nagarajan, Mark Nelson, Matthew K. O’Shea, Igor Otahal, Marlies
Ostermann, Mark Pais, Selva Panchatsharam, Danai Papakonstanti-
nou, Hassan Paraiso, Brij Patel, Natalie Pattison, Justin Pepperell,
Mark Peters, Mandeep Phull, Stefania Pintus, Jagtur Singh Pooni,
Frank Post, David Price, Rachel Prout, Nikolas Rae, Henrik Reschreiter,
Tim Reynolds, Neil Richardson, Mark Roberts, Devender Roberts, Alis-
tair Rose, Guy Rousseau, Brendan Ryan, Taranprit Saluja, Aarti Shah,
Prad Shanmuga, Anil Sharma, Anna Shawcross, Jeremy Sizer, Manu
Shankar-Hari, Richard Smith, Catherine Snelson, Nick Spittle, Nikki
Staines, Tom Stambach, Richard Stewart, Pradeep Subudhi, Tamas
Szakmany, Kate Tatham, Jo Thomas, Chris Thompson, Robert Thomp-
son, Ascanio Tridente, Darell Tupper-Carey, Mary Twagira, Andrew
Ustianowski, Nick Vallotton, Lisa Vincent-Smith, Shico Visuvanathan,
Alan Vuylsteke, SamWaddy, Rachel Wake, AndrewWalden, Ingeborg
Welters, Tony Whitehouse, Paul Whittaker, Ashley Whittington, Pad-
masayee Papineni, Meme Wijesinghe, Martin Williams, Lawrence
Wilson, Sarah Cole, Stephen Winchester, Martin Wiselka, Adam Wol-
verson, Daniel G Wooton, Andrew Workman, Bryan Yates, Peter
Young.
Author contributors
JTS, LS, MGS developed the concept of the follow up study. JTS, LS,
LWS, TMD, EJ, WLS, CB, DJL, MC, JMcP, NL, EMH, DM, CR, AH, LT, PB,
and the ISARIC Global Covid-19 follow up working group developed
the follow up protocol and methodology. ISARIC4C investigators iden-
tified participants during the acute admission and entered acute
phase data. PB, CD, HH, RS, JH, AG coordinated follow up survey distri-
bution, data entry, AG, AC, LG conducted telephone follow up. LS, JTS,
GC, HH coordinated resources. LS, JTS, TMD, EP, AD, PO, EH, ABD were
involved in data visualisation. TMD, EP, LS, JTS, MEO’H, PJMO, CH,
CEH, JKB, ABD, MGS analysed and interpreted the data. LS, TMD, EP,
JTS wrote the original draft of the manuscript. All authors reviewed,
and revised the manuscript prior to submission. JTS is the guarantor.
Declaration of Interests
CRD declares funding from the Medical Research Council, UK. JM
reports a University of Cambridge Research Fellowship. WSL reports
unrestricted investigator-initiated research funding from Pfizer for
an unrelated multi-centre study in pneumonia, in which WSL is the
CI and UK NIHR research funding for unrelated clinical trials in the
fields of COVID-19, tuberculosis and community-acquired pneumo-
nia. WSL’s role on the Joint Committee on Vaccination and Immunisa-
tion (JCVI), UK and chair of COVID-19 Immunisation and as National
Lead on British Thoracic Society community acquired pneumonia
audit programme is unpaid and unrelated to this work. CB declares a
British Heart Foundation Centre award, and a project grants from the
Chief Scientist Office, Scottish Government CSO Long Term Effects
and from Heart Research UK unrelated to this work. LG declares sup-
port from Pfizer & Gilead for attendance at an educational meeting in
Nov 2018 and April 2019, for cost of conference registration fee,
accommodation and flights unrelated to this work. PJMO reports per-
sonal fees from consultancy, grants from MRC, EU, NIHR Biomedicalfrom UK hospitals after Covid-19: A prospective, multicentre cohort
Lancet Regional Health - Europe (2021), https://doi.org/10.1016/j.
ARTICLE IN PRESS
JID: LANEPE [m5G;August 6, 2021;1:41]
12 L. Sigfrid et al. / The Lancet Regional Health - Europe 00 (2021) 100186Research Centres, MRC/GSK, Wellcome Trust, NIHR (HPRU) and NIHR
Senior Investigator Award. Personal fees from European Respiratory
Society, grants from MRC Global Challenge Research fund, other from
Nestle Discussion Forum (unpaid), Pfizer antivirals advisory board
(unpaid) outside of the submitted work and the role of President of
the British Society for Immunology was an unpaid appointment but
PJMO’s travel and accommodation at some meetings is provided by
the Society. MGS reports grants from the National Institute for Health
Research (NIHR), Medical Research Council. NIHR Health Protection
Research Unit (HPRU) in Emerging and Zoonotic Infections at Univer-
sity of Liverpool in partnership with Public Health England (PHE), in
collaboration with Liverpool School of Tropical Medicine and the Uni-
versity of Oxford. All other authors have no interests to declare.
Acknowledgements
This work uses data provided by patients and collected by the NHS
as part of their care and support #DataSavesLives. We are extremely
grateful to the 2,648 frontline NHS clinical and research staff and vol-
unteer medical students, who collected this data in challenging cir-
cumstances; and the generosity of the participants and their families
for their individual contributions in these difficult times. In particular,
the ISARIC Global Covid-19 Follow up working group and the ISARIC
global support centre. We would also like to acknowledge the sup-
port of Jeremy J Farrar.
Ethical approval
Ethical approval was given by the South Central - Oxford C
Research Ethics Committee in England ([ref 13]/SC/0149) and the
Scotland A Research Ethics Committee ([ref 20]/SS/0028).
Data sharing statement
Data are available for reuse through a secure data sharing plat-
form. Access is welcome through the ISARIC Independent Data and
Material Access Committee (https://isaric4c.net).
Transparency
The lead author (the manuscript's guarantor) affirms that the
manuscript is an honest, accurate, and transparent account of the
study being reported; that no important aspects of the study have
been omitted; and that any discrepancies from the study as planned
(and, if relevant, registered) have been explained.
Dissemination plans
Dissemination to participants and related patient and public com-
munities: ISARIC4C has a public facingwebsite [ISARIC4C.net] and twit-
ter account (@CCPUKstudy). We are engaging with print and internet
press, television, radio, news, and documentary programmemakers.
Funding statement
This work is supported by grants from: the National Institute for
Health Research (NIHR) [award CO-CIN-01], the Medical Research
Council [grant MC_PC_19059], the Imperial Biomedical Research Cen-
tre (NIHR Imperial BRC, grant P45058), the Health Protection
Research Unit (HPRU) in Respiratory Infections at Imperial College
London and NIHR HPRU in Emerging and Zoonotic Infections at Uni-
versity of Liverpool, both in partnership with Public Health England,
[NIHR award 200907], Wellcome Trust and Department for Interna-
tional Development [215091/Z/18/Z], and the Bill and Melinda Gates
Foundation [OPP1209135], and Liverpool Experimental Cancer Medi-
cine Centre (Grant Reference: C18616/A25153), NIHR BiomedicalPlease cite this article as: L. Sigfrid et al., Long Covid in adults discharged
study using the ISARIC WHO Clinical Characterisation Protocol, The
lanepe.2021.100186Research Centre at Imperial College London [IS-BRC-1215-20013], EU
Platform for European Preparedness Against (Re-) emerging
Epidemics 1 [FP7 project 602525] and NIHR Clinical Research Net-
work for providing infrastructure support for this research. LT is
a Wellcome Trust clinical career development fellow, supported by
grant number 205228/Z/16/Z. This research was funded in part, by
theWellcome Trust. PJMO is supported by a NIHR Senior Investigator
Award [award 201385]. The views expressed are those of the authors
and not necessarily those of the DHSC, DID, NIHR, MRC,
the Wellcome Trust or PHE.
Supplementary materials
Supplementary material associated with this article can be found
in the online version at doi:10.1016/j.lanepe.2021.100186.References
[1] Carfì A, Bernabei R, Landi F, Group for the GAC-19 P-ACS. Persistent Symptoms in
Patients After Acute COVID-19. JAMA 2020;324:603–5.
[2] Sudre CH, Murray B, Varsavsky T, et al. Attributes and predictors of long COVID.
Nat Med 2021. doi: 10.1038/s41591-021-01292-y.
[3] Salehi S, Reddy S, Gholamrezanezhad A. Long-term Pulmonary Consequences of
Coronavirus Disease 2019 (COVID-19): What We Know and What to Expect. J
Thorac Imaging 2020;35:W87–9.
[4] Munblit D, Bobkova P, Spiridonova E, et al. Risk factors for long-term consequen-
ces of COVID-19 in hospitalised adults in Moscow using the ISARIC Global follow-
up protocol: StopCOVID cohort study. medRxiv 2021 2021.02.17.21251895.
[5] Huang C, Huang L, Wang Y, et al. 6-month consequences of COVID-19 in patients
discharged from hospital: a cohort study. Lancet 2021;397:220–32.
[6] Burki TK. Post-Ebola syndrome. Lancet Infect Dis 2016;16:780–1.
[7] Scott JT, Sesay FR, Massaquoi TA, Idriss BR, Sahr F, Semple MG. Post-Ebola Syn-
drome, Sierra Leone. Emerg Infect Dis 2016;22:641–6.
[8] Hung TM, Wills B, Clapham HE, Yacoub S, Turner HC. The Uncertainty Surround-
ing the Burden of Post-acute Consequences of Dengue Infection. Trends Parasitol
2019;35:673–6.
[9] Blettery M, Brunier L, Polomat K, et al. Brief Report: Management of Chronic Post-
Chikungunya Rheumatic Disease: The Martinican Experience. Arthritis Rheuma-
tol 2016;68:2817–24.
[10] Rawal G, Yadav S, Kumar R. Post-intensive care syndrome: An overview. J Transl
Intern Med 2017;5:90–2.
[11] NICE. COVID-19 rapid guideline: managing the long-term effects of COVID-19.
NICE Guidel. [NG188]; 2020 https://www.nice.org.uk/guidance/ng188 accessed
March 10, 2020.
[12] Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpa-
tients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet
2020;395:1054–62.
[13] Verity R, Okell LC, Dorigatti I, et al. Estimates of the severity of coronavirus disease
2019: a model-based analysis. Lancet Infect Dis 2020;20:669–77.
[14] Clark A, Jit M, Warren-Gash C, et al. Global, regional, and national estimates of the
population at increased risk of severe COVID-19 due to underlying health condi-
tions in 2020: a modelling study. Lancet Glob Heal 2020;8:E1003–17.
[15] National Institute for Demographic Studies. Demographics of COVID-19 deaths:
data and metadata. Covid-19 INED. https://dc-covid.site.ined.fr/en/data/.
(accessed March 10, 2020).
[16] Global Health 50/50. COVID-19: data disaggregated by age and sex. https://glob-
alhealth5050.org/covid19/age-and-sex-data/. (accessed March 12, 2020).
[17] Knight SR, Ho A, Pius R, et al. Risk stratification of patients admitted to hospital
with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: develop-
ment and validation of the 4C Mortality Score. BMJ 2020;370:m3339.
[18] Latronico N, Peli E, Rodella F, Novelli MP, Rasulo FA, Piva S. Three-Month Outcome
in Survivors of COVID-19 Associated Acute Respiratory Distress Syndrome. Prepr
with Lancet 2021. doi: 10.2139/ssrn.3749226.
[19] The Lancet. Facing up to long COVID. Lancet 2020;396:1861.
[20] ISARIC. ISARIC Clinical Characterisation Protocol (CCP): UK version. https://isar-
ic4c.net/protocols/ accessed Feb 1, 2020.
[21] ISARIC. WHO. ISARIC-4C Global. https://isaric.org/research/covid-19-clinical-
research-resources/clinical-characterisation-protocol-ccp/ accessed Feb 1, 2020.
[22] von Elm E, Altman DG, Egger M, et al. The Strengthening the Reporting of Obser-
vational Studies in Epidemiology (STROBE) Statement: Guidelines for Reporting
Observational Studies. J Clin Epidemiol 2008;61:344–9.
[23] Marshall JC, Murthy S, Diaz J, et al. A minimal common outcome measure set for
COVID-19 clinical research. Lancet Infect Dis 2020;20:e192–7.
[24] Gupta RK, Harrison EM, Ho A, et al. Development and validation of the ISA-
RIC 4C Deterioration model for adults hospitalised with COVID-19: a pro-
spective cohort study. Lancet Respir Med 2021;0. doi: 10.1016/S2213-2600
(20)30559-2.
[25] Washington Group on Disability Statistics. The Washington Group Short Set on
Functioning (WG-SS). WG-SS. https://www.washingtongroup-disability.com/
question-sets/wg-short-set-on-functioning-wg-ss/(accessed Feb 1, 2020).from UK hospitals after Covid-19: A prospective, multicentre cohort
Lancet Regional Health - Europe (2021), https://doi.org/10.1016/j.
ARTICLE IN PRESS
JID: LANEPE [m5G;August 6, 2021;1:41]
L. Sigfrid et al. / The Lancet Regional Health - Europe 00 (2021) 100186 13[26] Medical Research Council. 1952 MRC Breathlessness Scale. https://mrc.ukri.org/
research/facilities-and-resources-for-researchers/mrc-scales/mrc-dyspnoea-
scale-mrc-breathlessness-scale/(accessed Feb 1, 2020).
[27] EuroQol Research Foundation. EQ-5D-3L User Guide. https://euroqol.org/publica-
tions/user-guides accessed Feb 1, 2020.
[28] Devlin N, Parkin D, Browne J. Using the EQ-5D as a performance measurement
tool in the NHS. Health Econ 2010;19:886–905.
[29] Parkin D, Devlin N, Rice N. Statistical analysis of EQ-5D profiles: does the use of
value sets bias inference? Med Decis Making 2010;30:556–65.
[30] Docherty AB, Harrison EM, Green CA, et al. Features of 20 133 UK patients in hos-
pital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: pro-
spective observational cohort study. BMJ 2020;369:m1985.
[31] Abate S, Ahmed AS, Mantfardo B, Basu B. Rate of Intensive Care Unit admission
and outcomes among patients with coronavirus: A systematic review and Meta-
analysis. PLoS One 2020;15:e0235653.
[32] Karagiannidis C, Mostert C, Hentschker C, et al. Case characteristics,
resource use, and outcomes of 10 021 patients with COVID-19 admitted to
920 German hospitals: an observational study. Lancet Respir Med
2020;8:853–62.Please cite this article as: L. Sigfrid et al., Long Covid in adults discharged
study using the ISARIC WHO Clinical Characterisation Protocol, The
lanepe.2021.100186[33] Escher M, Hall M, Baillie JK, et al. ISARIC Clinical Data Report 10 February 2021.
medRxiv 2021 2020.07.17.20155218.
[34] Office for National Statistics. Which occupations have the highest potential expo-
sure to the coronavirus (COVID-19)? https://www.ons.gov.uk/employmentand-
labourmarket/peopleinwork/employmentandemployeetypes/articles/whichoc-
cupationshavethehighestpotentialexposuretothecoronaviruscovid19/2020-05-11
accessed March 12, 2020.
[35] Takahashi T, Ellingson MK, Wong P, et al. Sex differences in immune responses
that underlie COVID-19 disease outcomes. Nature 2020;588:315–20.
[36] Office for National Statistics. COVID-19 Schools Infection Survey Round 2, Eng-
land: December 2020. https://www.ons.gov.uk/peoplepopulationandcommun-
ity/healthandsocialcare/conditionsanddiseases/bulletins/covid19schoolsinfec-
tionsurveyround2england/december2020 accessed March 12, 2020.
[37] Fincham Jack E. Response rates and responsiveness for surveys, standards, and
the Journal. Am. J. Pharm. Educ. 2008;72:43.
[38] Barsky A, Peekna H, Borus J. Somatic symptom reporting in women and men. J.
Gen. Intern. Med. 2001;16:266–75.
[39] PHOSP Covid. Long-term follow up of adults hospitalised with COVID-19. Pro-
spectively registered. ISRCTN Regist 2020.from UK hospitals after Covid-19: A prospective, multicentre cohort
Lancet Regional Health - Europe (2021), https://doi.org/10.1016/j.
